Dermapharm Holding SE Statistics

Total Valuation

Dermapharm Holding SE has a market cap or net worth of GBP 1.79 billion. The enterprise value is 2.55 billion.

Market Cap	1.79B
Enterprise Value	2.55B

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	Jun 28, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.23%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	10.50M

Valuation Ratios

The trailing PE ratio is 23.74.

PE Ratio	23.74
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.61, with an EV/FCF ratio of 19.52.

EV / Earnings	33.86
EV / Sales	2.60
EV / EBITDA	12.61
EV / EBIT	14.17
EV / FCF	19.52

Financial Position

The company has a current ratio of 1.66, with a Debt / Equity ratio of 1.74.

Current Ratio	1.66
Quick Ratio	0.65
Debt / Equity	1.74
Debt / EBITDA	4.26
Debt / FCF	6.53
Interest Coverage	3.70

Financial Efficiency

Return on equity (ROE) is 15.75% and return on invested capital (ROIC) is 8.23%.

Return on Equity (ROE)	15.75%
Return on Assets (ROA)	6.26%
Return on Invested Capital (ROIC)	8.23%
Return on Capital Employed (ROCE)	12.26%
Revenue Per Employee	279,347
Profits Per Employee	21,556
Employee Count	3,497
Asset Turnover	0.55
Inventory Turnover	1.29

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.07% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+4.07%
50-Day Moving Average	38.39
200-Day Moving Average	35.46
Relative Strength Index (RSI)	53.04
Average Volume (20 Days)	23,274

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Dermapharm Holding SE had revenue of GBP 976.88 million and earned 75.38 million in profits. Earnings per share was 1.40.

Revenue	976.88M
Gross Profit	611.06M
Operating Income	178.42M
Pretax Income	117.97M
Net Income	75.38M
EBITDA	195.32M
EBIT	178.42M
Earnings Per Share (EPS)	1.40

Full Income Statement

Balance Sheet

The company has 98.66 million in cash and 853.36 million in debt, giving a net cash position of -754.70 million.

Cash & Cash Equivalents	98.66M
Total Debt	853.36M
Net Cash	-754.70M
Net Cash Per Share	n/a
Equity (Book Value)	490.16M
Book Value Per Share	9.00
Working Capital	206.51M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 163.73 million and capital expenditures -33.00 million, giving a free cash flow of 130.73 million.

Operating Cash Flow	163.73M
Capital Expenditures	-33.00M
Free Cash Flow	130.73M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 62.55%, with operating and profit margins of 18.26% and 7.72%.

Gross Margin	62.55%
Operating Margin	18.26%
Pretax Margin	12.08%
Profit Margin	7.72%
EBITDA Margin	19.99%
EBIT Margin	18.26%
FCF Margin	13.38%

Dividends & Yields

Dermapharm Holding SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	-17.00%
Years of Dividend Growth	n/a
Payout Ratio	52.30%
Buyback Yield	-0.23%
Shareholder Yield	-0.23%
Earnings Yield	4.21%
FCF Yield	7.30%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Dermapharm Holding SE has an Altman Z-Score of 2.07. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.07
Piotroski F-Score	n/a